|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, March 12, 2010 ) NY, NY TapeBeat.Com, the news and research portal for the serious investor is proud to present information regarding Poniard Pharmaceuticals, Inc., (Public, NASDAQ:PARD). Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. PARD received favorable clinical results in a phase II study on Picoplatin and much attention for the company in general.
Relativley unknown to investors is PARDÂ’s PMD 1186 drug candidate. Cancer and Biology TherapyÂ’s May TherapyÂ’s May issue has two abstracts regarding PND 1186, and an article appearing with comments from Michael D. Schaller, Department of Biochemistry, West Virginia University and Steven M. Frisch, Mary Babb Randolph Cancer Center and Department of Biochemistry, West Virginia University.
It seems noteworthy that comments by both a Senior Rodman Analyst and an IPO Attorney Watchdog have been made within the last week while this newer information is pending for publication. How significant this drug candidate is will be discussed by the professional community now that the information is presented in a professional journal. How this information effects the bottom line for PARD will be arguably discussed by analysts, investors, traders and those that take ‘short positions’ in the stock of PARD.
An article appeared in biomedreports.com written by Rodman & Renshaw’s Managing Director and Senior Biotechnology Analyst, Simos Simeonidis, Ph.D, who among other things stated that “Yes, we believe that there is a pharma company out there that likes picoplatin.” Rodman & Renshaw’s website states that "Since 2003, Rodman has completed over 230 transactions and raised over $3.7 billion for healthcare companies." Further positive comments were made by Gene Quinn, Patent Attorney and founder at IPWatchdog.com. We encourage you to read these articles at biomedreports.com and IPWatchdog.com for a better contextual understanding and also subscribe to biomedreports.com FDA calendar, which is a useful tool.
Remember where you heard it first. For futher information, the links mentioned, or to sign up for advance alerts visit us at TapeBeat.Com click here.
Philip Runfeldt
Position: Long PARD
By viewing this information you agree to the disclaimer found on the website. The opinions expressed are that of the individual contributor(s). Neither the company releasing this information, nor the contributor(s) are associated with the company(s) mentioned or acting on their behalf. None are certified financial advisor(s) or professional analysts. This is not a solicitation to trade any security or a recommendation. Please do your own due diligence as, trading in equities may occur loss of your principal.
TapeBeat.Com
Philip Runfeldt
888-209-2749
admin@TapeBeat.Com 
Source: EmailWire.com
|
|
|
|
